Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

Overview of the Migraine Drugs MarketThe global Migraine Drugs Market is valued at $6.37 billion in 2024 and is projected to ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the ...

Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...

The study will evaluate Sinaptica’s SinaptiStim in delivering simultaneous transcranial magnetic and alternating current ...

Primary safety endpoint met - No serious adverse events reported over 3-monthsRobust device performance - No device failure reported over 3-months Synergia Medical announces that its NAO.VNS™ device, ...

The NaviFUS system uses transcranial focused ultrasound and therapeutic guidance tracking for drug delivery and neuromodulation, offering new hope for patients with brain cancer and drug-resistant ...

For example, some of these drugs can treat your migraine 2-4 hours into an attack, compared to older treatments that work best if taken within 30 minutes. New neuromodulation devices that use ...